Our Product Pipeline

Rubix’s clinical-stage pipeline is based on synthetic regenerative compound molecules for the treatment of targeted regions with strong potential to evolve the intersection of implantable combination devices. Studies suggest that these compounds may facilitate physical interactions between synthetic and organic receptors that result in enhanced activity, offering new potential for a variety of diseases with unmet needs.

Therapeutic Pipeline

Project Hercules

Indication: Osteonecrosis

Project Apollo

Indication: MS, PLS & ALS

Project Kronos

Quantum Digital Therapeutic Informatics companion tool

Project Icarus

Indication: Glioma tumors (Primary target: DIPG; Secondary: GBM)

Better Health Outcomes is Our Mission